Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gen-Probe, Incorporated
ClinicalTrials.gov Identifier:
NCT00973362
First received: September 4, 2009
Last updated: November 9, 2016
Last verified: November 2016
  Purpose
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.

Condition Intervention Phase
Human Papillomavirus Infection
Device: APTIMA HPV Assay
Device: FDA-Approved HPV DNA Test
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens

Resource links provided by NLM:


Further study details as provided by Gen-Probe, Incorporated:

Primary Outcome Measures:
  • Adjunct Study Arm: Compare Assay Performance for Aptima HPV Assay to a FDA-Approved HPV Assay for Detecting CIN2+ [ Time Frame: Baseline Evaluation ]
    Adjunct 30+ yrs. Population: Aptima HPV Assay Performance for Detecting CIN2+: Compare Clinical Performance of the Aptima HPV Assay to a FDA-Approved HPV Assay for Detecting CIN2+

  • Adjunct Study Arm: Compare Assay Performance for FDA-Approved HPV DNA Assay to a FDA-Approved HPV Assay for Detecting CIN2+ [ Time Frame: Baseline Evaluation ]
    Adjunct Study Arm: 30+ yrs. Population: FDA-Approved HPV DNA Assay Performance for Detecting CIN2+: Compare Clinical Performance of the Aptima HPV Assay to a FDA-Approved HPV Assay for Detecting CIN2+


Secondary Outcome Measures:
  • ASC-US Study Arm: Aptima HPV Assay Performance for Detecting CIN2+ (All Biopsies) [ Time Frame: Baseline Evaluation ]
    ASC-US Study Arm: 21+ yrs. Population: Aptima HPV assay performance on Tigris System for detecting CIN2+ (All Biopsies)

  • ASC-US Study Arm: FDA-Approved HPV DNA Assay Performance for Detecting CIN2+ (All Biopsies) [ Time Frame: Baseline Evaluation ]
    ASC_US Study Arm: 21+ yrs. Population for Detecting CIN2+ (All Biopsies): FDA-Approved HPV DNA Assay


Enrollment: 12896
Study Start Date: March 2008
Study Completion Date: April 2014
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Adjunct (i.e. Normal Pap)
The Adjunct study will evaluate APTIMA HPV Assay clinical performance for detecting high-risk HPV types in female subjects 30+ years of age with negative (NILM) cytology results from routine Pap testing. This will be accomplished by evaluating the assay performance compared to known cervical disease status at baseline and after a 3-year follow-up period. A comparator FDA-Approved HPV DNA test is reported.
Device: APTIMA HPV Assay
The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer ("high-risk types"). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44).
Device: FDA-Approved HPV DNA Test
A FDA-Approved HPV DNA Test is used as the comparator assay.
ASC-US
The ASC-US study will evaluate the APTIMA HPV Assay clinical performance for detecting high-risk HPV types in subjects with ASC-US Pap test results from routine Pap testing and known cervical disease status (based on colposcopic biopsy results). A comparator FDA-Approved HPV DNA test is reported. There is no follow-up period.
Device: APTIMA HPV Assay
The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer ("high-risk types"). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44).
Device: FDA-Approved HPV DNA Test
A FDA-Approved HPV DNA Test is used as the comparator assay.

Detailed Description:
The primary objective of the clinical trial is to evaluate the APTIMA HPV Assay, using the TIGRIS System, in cervical cancer screening programs. This will be achieved by determining the performance of the assay for detecting high-risk human papillomavirus (HPV) types in women with known cervical disease status. The assay will be evaluated in sample populations of women with ASC-US Pap test results ("ASC-US results") and women 30 years of age or older ("30+ years of age") with negative (NILM) cytology results.
  Eligibility

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female 21 years or older (ASC-US study only)
  • Female 30 years or older (Adjunct and ASC-US studies)
  • Subject attending a participating clinic and undergoing a Pap screening exam during the clinic visit
  • Ability to comprehend and sign an IRB-approved Informed Consent Form

Exclusion Criteria:

  • Diagnosis of cervical disease (cancer or precancerous condition) in the past 12 months
  • Abnormal Pap test result in the past 12 months
  • Subject under 18 years of age and consenting to the study without the presence of their parent or legal guardian
  • Known to be pregnant
  • Having an illness or medical condition that could interfere with or affect the conduct, results, and/or completion of the clinical trial
  • Having an illness or medical condition that the investigator or physician feels would create an unacceptable risk to the subject if she enrolled into the clinical trial
  • Prior vaccination for HPV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00973362

Locations
United States, Arkansas
NEA Clinic Women's Clinic
Jonesboro, Arkansas, United States, 72401
United States, California
San Fernando Valley Research
Canoga Park, California, United States, 91306
Healthcare Partners of Monterey Park
Los Angeles, California, United States, 90015
Diverse Research Solutions
Oxnard, California, United States, 93030
REMEK
Pomona, California, United States, 91767
West Coast OB-Gyn
San Diego, California, United States, 92123
HealthCare Partners
Torrance, California, United States, 90503
Penninsula Research Associates
Torrance, California, United States, 90505
United States, Florida
Community Medical Research of South Florida
Miami, Florida, United States, 33141
Insignia Clinical Research
Tampa, Florida, United States, 33613
United States, Georgia
Emory University School of Medicine
Atlanta, Georgia, United States, 30303
United States, Indiana
Indiana Univ. School of Medicine Dept of Pathology Wishard Health Sciences
Indianapolis, Indiana, United States, 46202
United States, Michigan
Saginaw Valley Medical Research
Saginaw, Michigan, United States, 48604
United States, Missouri
PPS Clinical
Chesterfield, Missouri, United States, 63017
United States, Oklahoma
Planned Parenthood of Eastern Arkansas and Oklahoma
Tulsa, Oklahoma, United States, 74105
United States, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140
United States, Tennessee
Adams Patterson OB-GYN
Memphis, Tennessee, United States, 38120
Sponsors and Collaborators
Gen-Probe, Incorporated
Investigators
Study Director: Jennifer L Reid, PhD Gen-Probe, Incorporated
  More Information

Responsible Party: Gen-Probe, Incorporated
ClinicalTrials.gov Identifier: NCT00973362     History of Changes
Other Study ID Numbers: 2007HPVASCUS30
Study First Received: September 4, 2009
Results First Received: July 28, 2016
Last Updated: November 9, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Gen-Probe, Incorporated:
Cervix Cancer
Cervical Intraepithelial Neoplasia (CIN)
Human Papillomavirus Virus (HPV)
APTIMA HPV Assay
FDA-Approved HPV DNA Test
TIGRIS DTS (direct tube sampling) System
Clinical Sensitivity (%)
Clinical Specificity (%)
Positive Predictive Value [PPV] (%)
Negative Predictive Value [NPV] (%)
Atypical Squamous Cells Undetermined Significance (ASC-US)
Relative Risk

Additional relevant MeSH terms:
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections

ClinicalTrials.gov processed this record on April 27, 2017